Depression news and depression widget

The European Medicines Agency (EMEA) has been formally notified by Wyeth Europa Ltd of its decision to withdraw the application for a centralised marketing authorisation for the medicine Ellefore (desvenlafaxine) 50 mg, 100 mg and 200 mg prolonged-release tablets. Ellefore was expected to be used for the treatment of major depressive disorder. The application for marketing authorisation for Ellefore was submitted to the EMEA on 28 September 2007.

Title: How the Weather Affects Our MoodsCategory: health newscreated: 10/17/2008Last Editorial review: 10/17/2008

Once again we are beginning a new year. For many of us this signals an opportunity for making new beginnings in our lives. Unfortunately, although most of us start out full of resolve and determination, we end up falling short of our goals. We know we can benefit from change in our lives, but how do we make those changes become lasting ones? Try these tips to increase your chances of success.